 |
The Lattice (Official 3DHEALS Podcast)Author: 3DHEALS
Welcome to the Lattice podcast, the official podcast for 3DHEALS. This is where you will find fun but in-depth conversations (by founder Jenny Chen) with technological game-changers, creative minds, entrepreneurs, rule-breakers, and more. The conversations focus on using 3D technologies, like 3D printing and bioprinting, AR/VR, and in silico simulation, to reinvent healthcare and life sciences. This podcast will include AMA (Ask Me Anything) sessions, interviews, select past virtual event recordings, and other direct engagements with our Tribe.While there is no rule for our podcast content, the only rule we follow is to provide our listeners with a maximized return on their attention and time investment.Follow us on Facebook, Twitter, and Instagram @3dheals, and check out the links in the show notes. 3DHEALS Links: https://linktr.ee/3dheals DisclaimerThe content of this podcast is for informational and educational purposes only and does not constitute medical, legal, or financial advice. The views and opinions expressed by the host and guests are their own and do not necessarily reflect those of their employers, affiliates, or any associated organizations.While we discuss emerging technologies in healthcare and 3D printing, listeners should consult qualified professionals before making decisions based on the information shared. The mention of specific companies, products, or technologies does not imply endorsement.This podcast may reference early-stage innovations and concepts that are not yet FDA-approved or commercially available. Always follow regulatory guidelines and ethical standards when applying new technologies in clinical or professional settings.Would you like this disclaimer read aloud at the beginning of each episode, or placed in the show notes? Language: en-us Genres: Life Sciences, Science, Technology Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Episode #102| Can Bioprinting Reshape The Future of Immunology?
Episode 102
Thursday, 18 December, 2025
We explore how to move IVIG from donor scarcity to on‑demand manufacturing with tissue‑engineered bioreactors, and why that shift could lower costs, expand access, and improve consistency. We dig into polyclonal advantages, regulatory guardrails, scaling plans, and what success would mean for complex biologics beyond antibodies.• Defining a bioreactor that recreates human tissue niches• Why polyclonal IVIG remains essential across 100+ conditions• Limits of donor‑dependent plasma supply and regional variability• Complex therapeutics as a new manufacturing category• Cost targets of 10–100x reduction and CapEx shrink• Coffee‑cup reactors and near‑term validation milestones• Quality metrics including pathogen panels and glycosylation• Donor variability, blending strategies, and future immortalization• Clinical impact of moving from rationing to earlier use• Funding update and industry partnershipsPlease listen to the disclaimer at the end of this podcast.Show notes: https://3dheals.com/episode-102-can-bioprinting-bioreactor-reshape-the-future-of-immunology/About our guests:Dr. Melanie Matheu is an immunologist, inventor, and biotechnologist recognized for pioneering work in high-resolution tissue engineering and human immunology. She received her PhD in Physiology and Biophysics with a focus on Immunology from UC Irvine and completed postdoctoral training at VIB (Ghent University, Belgium) and UC San Francisco, where she specialized in 2-photon imaging and cellular immune responses. As founder of Prellis Biologics, Dr. Matheu brought forward laser-based tissue bioprinting to solve complex challenges in organ transplantation and therapeutic antibody discovery. She later co-founded Lyric Bio, where she serves as Chief Scientific Officer, advancing scalable biomanufacturing platforms and rapid human immune system modeling. Dr. Matheu has authored numerous peer-reviewed publications, holds multiple patents, and is a passionate advocate for innovation at the intersection of immunology and bioengineering.Kevin Shannon (Kayj) holds a degree in Molecular Biology from Princeton University and a MBA from Stanford Graduate School of Business. Kayj has held positions spanning the biotech ecosystem including start-ups, big pharma, venture capital, and consulting. As part of Corporate Strategy at Amgen, he worked with Amgen’s C-Suite to shape long-term strategy, built partnerships in novel therapeutic modalities, and led investments in emerging categories including cell & gene therapy, antibody engineering, single cell analysis, and quantum computing. Kayj has also consulted for multiple VC funds where he developed investment theses and performed Send us a textSupport the showSubscribe to our premium version and support the show. Follow us: Twitter Instagram Linkedin 3DHEALS WebsiteFacebookFacebook GroupYoutube channelAbout Pitch3D
